Logo image
Back
Repeat Biomarker Status in Breast Resection Specimens With Controlled Cold Ischemic Time
Journal article   Open access   Peer reviewed

Repeat Biomarker Status in Breast Resection Specimens With Controlled Cold Ischemic Time

Ellen G. East, Emily Roberts, Lili Zhao and Julie M. Jorns
American journal of clinical pathology, Vol.152(6), pp.766-774
12/01/2019
DOI: 10.1093/ajcp/aqz105
PMID: 31338514
url
https://doi.org/10.1093/ajcp/aqz105View
Published (Version of record) Open Access

Abstract

Objectives: Current College of American Pathologists/American Society of Clinical Oncology guidelines recommend cold ischemic time (CIT) of 1 hour or less for breast specimens to preserve biomarker expression, although some publications support an acceptable CIT of 4 hours or less. We retrospectively evaluated changes in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) from biopsy to resection specimens that were triaged to optimize CIT. Methods: We identified breast resection specimens collected after institutional implementation of a triage protocol. Clinicopathologic features were assessed. Results: In total, 295 excisions had a prior malignant diagnosis, with CIT of 4 hours or less and repeat ER, PR, and/or HER2; 230 (78%) had CIT of 1 hour or less, and 65 (22%) had CIT of more than 1 hour but 4 hours or less. Categorical change was seen in 10 (17.9%) of 56 with repeated ER/PR and 38 (13.3%) of 285 with repeated HER2 (of which five [1.8%] had meaningful change). Conclusions: When CIT is optimized, a meaningful change in biomarker expression is infrequent. This study supports that when specimens are appropriately triaged, CIT of 4 hours or less may be acceptable.
 Life Sciences & Biomedicine Pathology Science & Technology

Details

Metrics

20 Record Views
1 Times Cited - Web of Science
Logo image